Xbrane Biopharma (XBRANE) Q3 2026 earnings summary

Executive summary

• Q3 revenue was SEK 54.8m, led by Ximluci sales; the period loss narrowed to SEK 11.7m from SEK 24.0m.

• Lucamzi received FDA approval after quarter-end; U.S. launch preparations are underway with Valorum and STADA.

• Xdivane’s pivotal PK study completed recruitment; Ximluci was available in 24 markets and held 6% European volume share.

Financial highlights

• Q3 revenue was SEK 54.8m vs SEK 10.1m; Ximluci product sales were SEK 54.6m vs SEK 9.9m, with license revenue of SEK 0.2m in both periods.

• Q3 gross profit was SEK 8.9m vs a SEK 5.0m loss; operating loss was SEK 9.3m vs SEK 23.5m.

• Q3 administration expenses were SEK 5.4m and R&D expenses SEK 13.4m, including SEK 2.7m amortization; SEK 15.7m of development spending was capitalized.

• 9M revenue was SEK 118.9m vs SEK 143.3m; 9M net loss was SEK 36.2m vs profit of SEK 153.7m, including a prior-year SEK 168.9m divestment gain.

• Q3 operating cash flow was SEK 4.1m; total cash flow was SEK -12.3m. Cash and cash equivalents were SEK 37.4m at September 30.

Outlook and guidance

• Lucamzi’s U.S. launch is targeted for Q3 2027; preparations include production, launch materials and a Q-code application.

• Xdivane interim analysis is expected in Q2 2027, BLA submission is targeted for mid-2027, and U.S. launch could follow in early 2029.

• Further Ximluci deliveries to STADA are expected in coming quarters; production-cost reduction initiatives are expected to materialize during 2027.

• Xdarzane process development targets comparative analytical demonstration by mid-2027; commercialization-partner discussions are ongoing.